JP2005511748A5 - - Google Patents

Download PDF

Info

Publication number
JP2005511748A5
JP2005511748A5 JP2003551152A JP2003551152A JP2005511748A5 JP 2005511748 A5 JP2005511748 A5 JP 2005511748A5 JP 2003551152 A JP2003551152 A JP 2003551152A JP 2003551152 A JP2003551152 A JP 2003551152A JP 2005511748 A5 JP2005511748 A5 JP 2005511748A5
Authority
JP
Japan
Prior art keywords
prior
art
compounds described
compounds
phosphodiesterases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003551152A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005511748A (ja
Filing date
Publication date
Priority claimed from FR0115971A external-priority patent/FR2833266B1/fr
Application filed filed Critical
Publication of JP2005511748A publication Critical patent/JP2005511748A/ja
Publication of JP2005511748A5 publication Critical patent/JP2005511748A5/ja
Pending legal-status Critical Current

Links

JP2003551152A 2001-12-11 2002-12-05 Ｔ−ガンマ−９−デルタ−２リンパ球の活性のモジュレーターとして有用なホスホネート Pending JP2005511748A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0115971A FR2833266B1 (fr) 2001-12-11 2001-12-11 Nouveaux derives phosphonates, leur procede de preparation, leur utilisation comme modulateurs de l'activite des lymphocytes tgamma9 delta2
PCT/FR2002/004190 WO2003050128A1 (fr) 2001-12-11 2002-12-05 PHOSPHONATES UTILES COMME MODULATEURS DE L'ACTIVITE DES LYMPHOCYTES t-GAMMA-9-DELTA-2

Publications (2)

Publication Number Publication Date
JP2005511748A JP2005511748A (ja) 2005-04-28
JP2005511748A5 true JP2005511748A5 (enExample) 2010-04-08

Family

ID=8870319

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003551152A Pending JP2005511748A (ja) 2001-12-11 2002-12-05 Ｔ−ガンマ−９−デルタ−２リンパ球の活性のモジュレーターとして有用なホスホネート

Country Status (6)

Country Link
US (2) US20060241087A1 (enExample)
EP (1) EP1453840A1 (enExample)
JP (1) JP2005511748A (enExample)
AU (1) AU2002366577A1 (enExample)
FR (1) FR2833266B1 (enExample)
WO (1) WO2003050128A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0212666D0 (en) * 2002-05-31 2002-07-10 Secr Defence Immunogenic sequences
BRPI0417088A (pt) * 2003-12-02 2007-03-13 Innate Pharma ativador de célula t gama delta, composição farmacêutica, uso do ativador de célula t gama delta, composição de vacina, métodos para preparar um composto, e para ativar uma célula t gama delta, célula t gama delta, e, uso da mesma
US20070134273A1 (en) * 2004-02-10 2007-06-14 Francois Romagne Composition and method for the treatment of carcinoma
US20070218086A1 (en) * 2004-04-26 2007-09-20 Innate Pharma, S.A. Adjuvant Composition and Methods for Its Use
WO2006067635A2 (en) * 2004-12-20 2006-06-29 Innate Pharma S.A. USE OF Ϝδ T LYMPHOCYTE ACTIVATORS AS VACCINE ADJUVANT
BRPI0608926A2 (pt) * 2005-03-22 2010-11-03 Innate Pharma ativador de células t gamadelta, composição farmacêutica, uso de um ativador de células t gamadelta, composição de vacina, método de ativação de uma célula t gamadelta, célula t gamadelta, e, uso de uma célula t gamadelta
GB2443591B (en) * 2005-09-07 2010-04-28 Secr Defence Adjuvanted vaccine
WO2007039635A2 (en) * 2005-10-06 2007-04-12 Innate Pharma Phosphoantigen salts of organic bases and methods for their crystallization
WO2008012538A2 (en) 2006-07-25 2008-01-31 The Secretary Of State For Defence Live vaccine strains of francisella
EP2083830A1 (en) 2006-11-17 2009-08-05 Innate Pharma Improved methods of using phosphoantigen for the treatment of cancer
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
CN111432891B (zh) 2017-12-11 2024-01-02 宝洁公司 含膦酰基-磷酸根基团和阴离子基团的聚合物
EP3723701B1 (en) 2017-12-11 2025-08-06 The Procter & Gamble Company Method of making phosphono-phosphate containing compounds
WO2019118419A1 (en) * 2017-12-11 2019-06-20 The Procter & Gamble Company Compositions comprising multi-valent cations and phosphono-phosphate containing polymers
WO2019118416A1 (en) * 2017-12-11 2019-06-20 The Procter & Gamble Company Phosphono-phosphate containing compounds and polymers
MX391985B (es) * 2017-12-11 2025-03-21 Procter & Gamble Composiciones para el cuidado bucal que comprenden polimeros que contienen grupo fosfono-fosfato y anionico
MX390467B (es) 2017-12-11 2025-03-20 Procter & Gamble Composiciones para el cuidado bucal que comprenden polimeros que contienen grupos fosfonato y anionicos
JP7065513B2 (ja) * 2018-06-29 2022-05-12 国立研究開発法人産業技術総合研究所 有機リン化合物
EP3856206A1 (en) 2018-09-27 2021-08-04 Phosphogam, Inc. Methods and compositions for the expansion and use of allogeneic gamma/delta-t cells

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR6914868D0 (pt) * 1969-01-23 1973-03-20 & Co Inc Merck Processos quimicos
ZA774977B (en) * 1976-09-06 1978-06-28 Sab Soc Etudes Applic Biolog Process for the preparation of 1,2-expoxypropyl-phosphonic acid derivatives
US4924024A (en) * 1988-01-11 1990-05-08 E. R. Squibb & Sons, Inc. Phosphorus-containing squalene synthetase inhibitors, new intermediates and method
US5177239A (en) * 1989-07-18 1993-01-05 E. R. Squibb & Sons, Inc. Method for preparing a phosphonic acid ester
US5298655A (en) * 1991-09-27 1994-03-29 Merck & Co., Inc. Farnesyl pyrophosphate analogs
US5827838A (en) * 1992-10-06 1998-10-27 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno & Rijksuniversteit Te Leiden Method for the treatment of diseases related with protein isoprenylation
US5463181A (en) * 1993-02-23 1995-10-31 Merrell Dow Pharmaceuticals Inc. Farnesyl: protein transferase inhibitors as anticancer agents
WO1994019357A1 (en) * 1993-02-23 1994-09-01 Merrell Dow Pharmaceuticals Inc. Farnesyl:protein transferase inhibitors as anticancer agents
US5574025A (en) * 1994-10-26 1996-11-12 Merck & Co., Inc. Inhibitors of prenyl-protein transferases
IT1276162B1 (it) * 1995-11-23 1997-10-27 Baldacci Lab Spa Geranilgeranil-derivati,procedimento per la loro preparazione e relative composizioni farmaceutiche
FR2782721B1 (fr) * 1998-09-01 2000-11-03 Inst Nat Sante Rech Med Nouveaux composes phosphohalohydrines, procede de fabrication et applications
FR2782722B1 (fr) * 1998-09-01 2001-01-12 Inst Nat Sante Rech Med Nouveaux composes phosphoepoxydes, procede de fabrication et applications
JP4025019B2 (ja) * 1999-01-21 2007-12-19 中外製薬株式会社 ２−メチル−３−ブテニル−１−ピロリン酸の塩およびリンパ球処理剤
FR2791981B1 (fr) * 1999-04-06 2001-07-20 Inst Nat Sante Rech Med Composes inhibant selectivement les lymphocytes tgamma9delta2, et leurs applications
EP1169996A1 (de) * 2000-07-06 2002-01-09 Ernst Mühlbauer Kg Phosphonsäuren enthaltendes Dentalmaterial
DE10201458A1 (de) 2001-04-11 2002-10-17 Adelbert Bacher Intermediate und Enzyme des Mevalonat-unabhängigen Isoprenoidbiosyntheseweg
WO2003009855A2 (de) * 2001-07-20 2003-02-06 Bioagency Ag Organo-phosphorverbindungen zur aktivierung von gamma/delta-t-zellen

Similar Documents

Publication Publication Date Title
JP2005511748A5 (enExample)
USD498335S1 (en) Exclusion cage for use with bird feeders
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
AU2001272735A1 (en) Novel physiologically active peptide and use thereof
DE60320007D1 (de) Phenethanolamin-derivate zur behandlung von atemwegserkrankungen
CA2515596A1 (en) Cannabinoid receptor ligands and uses thereof
WO2005112945A3 (en) Synthesis of tetracyclines and analogues thereof
DE60311272D1 (de) Neue purin- oder pyrrolol(2,3-d)pyrimidin-2-carbonsäurenitrile zur behandlung von mit cysteinproteaseaktivität assoziierten krankheiten
DE60325209D1 (de) Diarylharnstoffderivate, die sich zur behandlung von proteinkinaseabhängigen krankheiten eignen
WO2005023083A3 (en) Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
WO2003009855A3 (de) Organo-phosphorverbindungen zur aktivierung von gamma/delta-t-zellen
ATE429156T1 (de) Nahrungsergänzung zur behandlung von makula degeneration
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
DE602006008641D1 (de) Herstellung und anwendung von tetrahydropyrrolo ä3, 2-cüpyridin-4-onderivaten zur behandlung von obesitas und psychiatrischen und neurologischen erkrankungen
USD507034S1 (en) Fish hook design
EP1590041A4 (en) TREATMENT OF DENTISTRY DISEASE WITH PHOTOSENSIBILIZERS
JP2005511619A5 (enExample)
CA2489140A1 (en) Dosage form containing pantoprazole as active ingredient
WO2004056768A3 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
SI1509085T1 (sl) Fosfonati in njihovi derivati kot ojačevalci aktivnosti insekticidov
WO2003024996A3 (de) Antibakterielle makrozyklen
ATE548048T1 (de) Oncomodulin zur behandlung von neurologishen erkrankungen
JP2008513427A5 (enExample)
JP2006505577A5 (enExample)
WO2003028536A3 (en) Methods for diagnosing and treating heart disease